Somatostatin analogue continuation upon progression in patients with gastroenteropancreatic neuroendocrine tumour (SAUNA trial): a randomised controlled trial protocol

Introduction Gastroenteropancreatic neuroendocrine tumours (GEP NET) are malignant neoplasms that impact survival. Somatostatin analogues (SSA) are used for treating hormonal symptoms caused by GEP NET and have antiproliferative effects. They are used as first-line therapy in patients with advanced...

Popoln opis

Bibliografske podrobnosti

Principais autores:	Suzanne Polinder, Ivan Borbath, Marc Peeters, Philippe Beutels, Elke Smits, Iris Verhaegen, Ella Roelant, Wouter Dercksen, Stella Heemskerk, Siddharth Chhajlani, Jelka Kuiper, Christophe M Deroose, Isolde Van der Massen, Annemiek Walenkamp, Wouter W de Herder, Johannes Hofland, Timon Vandamme
Format:	Artigo
Jezik:	Inglês
Izdano:	BMJ Publishing Group 2025-07-01
Serija:	BMJ Open
Online dostop:	https://bmjopen.bmj.com/content/15/7/e099996.full
Oznake:	Označite Brez oznak, prvi označite!